Andrew Berchuck
Overview
Explore the profile of Andrew Berchuck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
350
Citations
11893
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meagher N, Kobel M, Karnezis A, Talhouk A, Anglesio M, Berchuck A, et al.
J Pathol
. 2025 Mar;
PMID: 40028669
Mucinous ovarian carcinoma (MOC) is a rare histotype of epithelial ovarian cancer. Its origins are obscure: while many mucinous tumours in the ovary are metastases from the gastrointestinal tract, MOC...
2.
Nagle C, Ibiebele T, Na R, Bandera E, Cramer D, Doherty J, et al.
Am J Clin Nutr
. 2025 Feb;
PMID: 39921094
Background: Prognosis after a diagnosis of invasive epithelial ovarian cancer is poor. Some studies have suggested modifiable behaviors, like diet, are associated with survival but the evidence is inconsistent. Objectives:...
3.
Feng J, Rouse C, Taylor L, Garcia S, Nguyen E, Coogan I, et al.
Int J Mol Sci
. 2025 Jan;
26(1.
PMID: 39796176
The mortality rate of ovarian cancer (OC) remains the highest among female gynecological malignancies. Advanced age is the highest risk factor for OC development and progression, yet little is known...
4.
Meernik C, Chen Q, Wilson L, Joshi A, Rahman F, Pisu M, et al.
Am J Epidemiol
. 2024 Oct;
PMID: 39479786
Racial differences in healthcare access (HCA) may contribute to disparities in ovarian cancer (OC) survival. We used structural equation models (SEM) to examine associations between race and HCA domains (affordability,...
5.
Liu J, Berchuck A, Backes F, Cohen J, Grisham R, Leath C, et al.
J Natl Compr Canc Netw
. 2024 Oct;
22(8):512-519.
PMID: 39413835
The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of...
6.
Feng J, Rouse C, Coogan I, Byrd O, Nguyen E, Taylor L, et al.
bioRxiv
. 2024 Sep;
PMID: 39314468
Significance: Aging microenvironment of OC may be regulated by S100a8 and S100a9 secreted by adipocytes, preadipocytes, or neutrophils through affecting the lipid metabolism, such as FFA (18:3).
7.
Peters P, Whitaker R, Lim F, Russell S, Bloom E, Pollara J, et al.
Neoplasia
. 2024 Sep;
57:101056.
PMID: 39276533
Single agent immune checkpoint inhibitors have been ineffective for patients with advanced stage and recurrent high grade serous ovarian cancer (HGSOC). Using pre-clinical models of HGSOC, we evaluated the anti-tumor...
8.
Meernik C, Osazuwa-Peters O, Wilson L, Joshi A, Pisu M, Liang M, et al.
Gynecol Oncol
. 2024 Aug;
190:146-152.
PMID: 39213779
Objective: Ovarian cancer has poor 5-year survival, particularly among non-Hispanic (NH) Black patients. Efforts to identify patients at high-risk of functional limitations and frailty may improve outcomes. In this study,...
9.
Nagle C, Ibiebele T, Bandera E, Cramer D, Doherty J, Giles G, et al.
Br J Cancer
. 2024 Jul;
131(6):1043-1049.
PMID: 39026080
Background: Tea and coffee are the most frequently consumed beverages in the world. Green tea in particular contains compounds with potential anti-cancer effects, but its association with survival after ovarian...
10.
Kaur P, Berchuck A, Chase A, Grout B, Deurloo C, Pearce L, et al.
Neoplasia
. 2024 Jul;
56:101026.
PMID: 38972207
Objectives: There is an active debate regarding whether metformin use improves survival in people with ovarian cancer. We examined this issue using methods designed to avoid immortal time bias-as bias...